A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice
Pharmaceutical Sciences Asia
Immune checkpoint inhibitors (ICIs) have significantly driven the oncology treatment landscape as they immensely shift better clinical outcomes among various type of cancers. Challenges of using this approach are, without doubt, the immune related adverse events (IrAEs). These can have vital impact to affect multiple organs and some cases lead to fatality. Therefore, risk stratification should be cautiously taken into consideration while clinicians are dealing with ICIs. In this article, thedoi:10.29090/psa.2020.02.019.0095 fatcat:uneck5atqnfkpffsz7xpxdrjda